NCT06220721 Reducing the Risk of Chronic Hypertension and Improving Vascular Function Following Preeclampsia
| NCT ID | NCT06220721 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Medical College of Wisconsin |
| Condition | Hypertension, Pregnancy-Induced |
| Study Type | INTERVENTIONAL |
| Enrollment | 618 participants |
| Start Date | 2024-10-23 |
| Primary Completion | 2029-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 618 participants in total. It began in 2024-10-23 with a primary completion date of 2029-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The long-term goal of our work is to evaluate the effect of intensive postpartum blood pressure control on maternal cardiovascular health, risk of chronic hypertension, and reversal of vascular dysfunction generated by hypertensive disorders of pregnancy, thus attenuating the lifelong trajectory of cardiovascular disease risk.
Eligibility Criteria
Inclusion Criteria: * Hypertensive disorders of pregnancy (HDP) diagnosis, specifically gestational hypertension, preeclampsia, eclampsia, or HELLP syndrome, according to ACOG guidelines * Postpartum day 0-4 * Age ≥ 18 years * Able to communicate in English or in Spanish * Has an established OBGYN at an MCW or NU health system practice that has access to Epic electronic medical records. Exclusion Criteria: * Pre-gestational hypertension * Type 1 or type 2 diabetes mellitus * Admitted to intensive care unit at the time of screening * Diagnosed with HDP during postpartum readmission after discharge from delivery hospitalization * Getting discharged on the day of screening * Known allergy or contraindication to nifedipine ER * Inability or unwillingness to provide informed consent * Already taking long-acting antihypertensive medication for standard care * Maternal conditions that impact study outcomes: sickle cell disease, systemic lupus erythematosus
Contact & Investigator
Anna Palatnik, MD
PRINCIPAL INVESTIGATOR
Medical College of Wisconsin
Frequently Asked Questions
Who can join the NCT06220721 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Hypertension, Pregnancy-Induced. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06220721 currently recruiting?
Yes, NCT06220721 is actively recruiting participants. Contact the research team at alyhernandez@mcw.edu for enrollment information.
Where is the NCT06220721 trial being conducted?
This trial is being conducted at Chicago, United States, Milwaukee, United States.
Who is sponsoring the NCT06220721 clinical trial?
NCT06220721 is sponsored by Medical College of Wisconsin. The principal investigator is Anna Palatnik, MD at Medical College of Wisconsin. The trial plans to enroll 618 participants.